Biotest Aktiengesellschaft

XTRA:BIO3 Stock Report

Market Cap: €1.4b

Biotest Future Growth

Future criteria checks 4/6

Biotest is forecast to grow earnings and revenue by 23.4% and 6.3% per annum respectively while EPS is expected to decline by 0.1% per annum.

Key information

23.4%

Earnings growth rate

-0.1%

EPS growth rate

Biotechs earnings growth35.3%
Revenue growth rate6.3%
Future return on equityn/a
Analyst coverage

Low

Last updated10 Jan 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

XTRA:BIO3 - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202571259N/AN/A1
12/31/2024636-4N/AN/A1
12/31/2023568-74N/AN/A1
9/30/202365691-122-93N/A
6/30/2023511-38-146-117N/A
3/31/2023517-47-127-98N/A
12/31/2022516-32-70-40N/A
9/30/2022505-69-414N/A
6/30/2022511-653049N/A
3/31/2022512-545169N/A
12/31/2021516-631634N/A
9/30/2021514-28-324N/A
6/30/2021507-33-32-5N/A
3/31/2021507-35-49-22N/A
12/31/2020484-31-44-17N/A
9/30/2020466-34-74-40N/A
6/30/2020459-24-83-49N/A
3/31/2020439-15-70-36N/A
12/31/2019419-5-68-34N/A
9/30/2019406-9-74-19N/A
6/30/2019395-3-61-6N/A
3/31/2019390-6-81-26N/A
12/31/2018400-13-105-50N/A
9/30/201840518-123-16N/A
6/30/20184096-1006N/A
3/31/20184001-9215N/A
12/31/2017378-16-7234N/A
9/30/2017257-48-1258N/A
6/30/2017301-47N/A-8N/A
3/31/2017340-29N/A35N/A
12/31/20164086N/A66N/A
9/30/2016531128N/A51N/A
6/30/201652552N/A57N/A
3/31/201652636N/A44N/A
12/31/201553527N/A38N/A
9/30/2015590-88N/A62N/A
6/30/20156063N/A54N/A
3/31/201560216N/A15N/A
12/31/201458219N/A-11N/A
9/30/201454327N/A-26N/A
6/30/201452231N/A-28N/A
3/31/201450430N/A-1N/A
12/31/201350132N/A-7N/A
9/30/201348332N/A10N/A
6/30/201346329N/A20N/A
3/31/201345126N/A21N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: BIO3's forecast earnings growth (23.4% per year) is above the savings rate (0.6%).

Earnings vs Market: BIO3's earnings (23.4% per year) are forecast to grow faster than the German market (15% per year).

High Growth Earnings: BIO3's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: BIO3's revenue (6.3% per year) is forecast to grow faster than the German market (5.5% per year).

High Growth Revenue: BIO3's revenue (6.3% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if BIO3's Return on Equity is forecast to be high in 3 years time


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.